菌酶响应凝药物输送平台,用于触发抗真菌释放
Noel Vera-González1, Carly Deusenbery1, Veronica LaMastro1
1School Of Engineering, Institute for Biology, Engineering, and Medicine, Brown University, 184 Hope Street, Providence, RI, 02912, USA.
Advanced healthcare materials
|August 30, 2024
概括
新的对真菌敏感的水凝在遇到真菌酶时降解,释放抗真菌脂质体,用于向感染治疗. 这种方法有效地根除了Candida albicans,同时最大限度地降低了药物毒性和耐药性.
科学领域:
- 生物材料科学 生物材料科学
- 菌类学 菌类学是指菌类学.
- 药物运输 药物运输 药物运输
背景情况:
- 真菌感染,特别是由Candida spp.引起的真菌感染,对健康构成重大风险.
- 目前的抗真菌治疗面临挑战,包括毒性和抗真菌耐药性的出现.
- 有毒的Candida albicans分泌的阿斯巴巴特蛋白酶 (SAPS) 促进组织入侵.
研究的目的:
- 开发一种新型的对真菌有反应的水凝,用于触发抗真菌药物输送.
- 为了研究水凝在对真菌酶的反应中降解的过程.
- 评估开发的药物输送系统的有效性和安全性.
主要方法:
- 水凝骨干功能化,具有Sap可切割的序列.
- 在水凝矩阵内封装脂质体抗真菌药物.
- 在Saps.的存在下评估水凝降解动力学.
- 对抗真菌释放特征的评估和体外对Candida albicans的疗效.
- 使用小鼠纤维细胞和红细胞进行细胞毒性测定.
主要成果:
- 在Candida albicans的Saps存在时,水凝显示出有效的降解.
- 脂质体抗真菌释放动力学与水凝降解相关.
- 含有抗真菌物质的水凝成功地在体外消除了Candida albicans培养物.
- 水凝系统在无菌的小鼠伤口液中保持稳定.
- 降解产品对哺乳动物细胞没有显著的细胞毒性.
结论:
- 响应真菌的水凝为局部,按需的抗真菌药物递送提供了一个有前途的平台.
- 这个系统可以提高治疗真菌感染的疗效.
- 这种方法有可能减少对抗真菌药物的全身暴露,并对抗耐药性.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...